What is your role in the LWNVIVAT project

As the project coordinator of this European initiative, I manage the grant and consortium agreements. I also foster collaboration among partners and ensure the project meets its objectives and timelines. Additionally, as a principal investigator at IrsiCaixa, I lead Work Packages 5 and 6, handled by my research group, Immunology.

How did you develop the idea for the LWNVIVAT project?

The West Nile virus spreads globally, causing outbreaks every year. It is an emerging pathogen with increasing significance in global health. Developing treatment and prevention methods is crucial. Our team believes our work can benefit the global population. To tackle this virus, we leverage the consortium’s expertise in immunology, virology, protein modeling, protein production, and vaccine and antibody development. Collaborating with top European teams in the LWNVIVAT project makes me very proud.

What is the primary goal of your research areas within the LWNVIVAT project?

My research focuses on defining the immunogenicity of vaccine prototypes designed, selected, and produced in other work packages. To accomplish this, we will conduct in vivo immunogenicity studies. Additionally, my team generates antibodies against proteins found on the West Nile virus surface.

Why did you decide to focus on developing a vaccine and antibodies?

The West Nile virus ranks among the most widespread mosquito-borne pathogens. While 80% of infected individuals show no symptoms, the fatality rate can reach 30% in immunosuppressed individuals and those over 60. Currently, no prophylaxis or treatment exists. Our goal is to develop a vaccine that protects against infection and disease. Furthermore, we aim to create therapeutic antibodies that accelerate recovery and reduce disease severity in infected individuals.

What are your latest findings, and what are the next steps for your research?

We are in the project’s initial phase, focusing on administrative, communication, and exploitation aspects. However, we are eager to analyze the immunogenicity of the first vaccine candidates, which will be ready soon.